TA
MXCT icon

Tamarack Advisers’s MaxCyte MXCT Stock Holding History

Tamarack Advisers’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$495K – 39
2023
Q1 		$495K Hold
100,000
– – 0.18% 33
2022
Q4 		$546K Buy
100,000
+17,901
+22% +$110K 0.28% 33
2022
Q3 		$534K Buy
+82,099
New +$458K 0.31% 39

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Tamarack Advisers's MXCT Position: Q2 2023 in Review

Tamarack Advisers sold out of MaxCyte (MXCT) in Q2 2023, closing a stake of 100,000 shares — an estimated $495K sold.

Tamarack Advisers first reported a position in MXCT in Q3 2022 and held it in 3 quarters. The position peaked at $546K in Q4 2022. 116 funds tracked by Wall St. Rank hold MXCT as of Q2 2023.

  • Tamarack Advisers reported no remaining MaxCyte position as of Q2 2023 after selling out during the quarter.
  • Tamarack Advisers sold 100,000 MaxCyte shares in Q2 2023, an estimated $495K.
  • Tamarack Advisers first reported a position in MaxCyte in Q3 2022 and held it in 3 quarters.
  • Tamarack Advisers's MaxCyte position peaked at $546K in Q4 2022.
  • 116 funds tracked by Wall St. Rank held MaxCyte as of Q2 2023.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.